GlassScriptPhysician profile
Charles D Rape
NPI 1932183464
$5,754.07
in general payments reported to CMS, 2019-2025
21 companies · $866 in 2025
The $866 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,042 · 2022: $1,443 · 2023: $503 · 2024: $1,900 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,260 · Travel and Lodging: $943 · Education: $66.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,259.70 |
| Travel and Lodging | $943.29 |
| Education | $66.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,115.75 | 2021-2024 | Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $968.13 | 2021-2025 | Intellis Adaptivestim, Synchromedii |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $954.77 | 2021-2025 | Relistor |
| Nalu Medical, INC. | $873.13 | 2021-2025 | Nalu Neurostimulation System |
| Collegium Pharmaceutical, INC. | $528.44 | 2021-2025 | Xtampza |
| Abbott Laboratories | $491.12 | 2021-2024 | Eterna |
| Averitas Pharma INC. | $127.72 | 2023-2024 | Qutenza |
| Si-Bone, INC. | $127.45 | 2021 | |
| Nevro Corp. | $112.42 | 2022-2024 | Senza |
| Paratek Pharmaceuticals, INC. | $104.14 | 2024 | Nuzyra |
| Scilex Pharmaceuticals INC. | $63.85 | 2022 | |
| Ge Healthcare | $49.54 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $48.93 | 2024-2025 | |
| Relievant Medsystems, INC. | $34.10 | 2022-2023 | Intracept |
| Tersera Therapeutics LLC | $29.20 | 2024 | Prialt |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $26.39 | 2022 | |
| Biotronik Nro, INC. | $24.54 | 2025 | Prospera |
| Pfizer INC. | $21.58 | 2021 | |
| Hikma Pharmaceuticals USA | $21.00 | 2024 | Kloxxado |
| Spr Therapeutics, INC | $16.37 | 2024 | Sprint Pns System |
| Redhill Biopharma INC. | $15.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Rape listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.